Literature DB >> 6145487

Striatal glutamatergic function: modifications following specific lesions.

P J Roberts, G J McBean, N A Sharif, E M Thomas.   

Abstract

The effects of specific lesions of the striatum: (a) hemidecortication; (b) striatal injection of (+/-) ibotenate; and (c) 6-hydroxydopamine injections into the substantia nigra, were investigated on specific [3H]glutamate binding to striatal membranes. One month after decortication, there was a substantial reduction of calcium-dependent, stimulated glutamate release from striatal slices, indicating effective loss of glutamatergic fibres. Striatal glutamate binding increased by approximately 30% and this supersensitivity could be attributed solely to an increased receptor density. Ibotenate lesions which destroy target neurones for the glutamatergic fibres (sparing terminals), reduced glutamate binding in the striatum, as did nigral 6-OHDA lesions which delete striatal dopaminergic terminals. This finding supports the concept of there being glutamate receptors on pre-synaptic dopamine terminals in the striatum, involved in regulation of dopamine release. 6-OHDA lesions also result in a supersensitivity of the dopamine receptors localized on the cortico-striatal afferent terminals, as evidenced by the enhanced ability of dopamine to inhibit the K+-evoked, calcium-dependent release of endogenous striatal glutamate.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6145487     DOI: 10.1016/0006-8993(82)90197-4

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  14 in total

1.  Modulation of MK-801 response by dopaminergic agents in mice.

Authors:  A Verma; S K Kulkarni
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Functional and biochemical characteristics of a putative quisqualate-type receptor in rat striatum: effect of brain lesions.

Authors:  M I Rudolph; G Bustos
Journal:  Neurochem Res       Date:  1986-11       Impact factor: 3.996

3.  Spontaneous release of endogenous aspartate and glutamate from rat striatal slices is increased following destruction of local neurons by ibotenic acid.

Authors:  S P Arnerić; J I Woo; M P Meeley; D J Reis
Journal:  Neurochem Res       Date:  1988-05       Impact factor: 3.996

Review 4.  Presynaptic regulation of dopaminergic transmission in the striatum.

Authors:  J Glowinski; A Chéramy; R Romo; L Barbeito
Journal:  Cell Mol Neurobiol       Date:  1988-03       Impact factor: 5.046

Review 5.  Pathogenesis of Alzheimer's disease--beyond the cholinergic hypothesis: discussion paper.

Authors:  P J Harrison
Journal:  J R Soc Med       Date:  1986-06       Impact factor: 5.344

6.  Interactions of glutamate and dopamine in a computational model of the striatum.

Authors:  R Kötter; J Wickens
Journal:  J Comput Neurosci       Date:  1995-09       Impact factor: 1.621

7.  Release of endogenous dopamine, 3,4-dihydroxyphenylacetic acid, and amino acid transmitters from rat striatal slices.

Authors:  R S Flint; J M Murphy; W J McBride
Journal:  Neurochem Res       Date:  1985-04       Impact factor: 3.996

8.  Further contribution to the study of corticostriatal glutamatergic and nigrostriatal dopaminergic interactions within the striatal network: an in vivo voltammetric investigation.

Authors:  C Forni; N Dusticier; A Nieoullon
Journal:  Amino Acids       Date:  1992-02       Impact factor: 3.520

9.  Neuronal dependence of extracellular dopamine, acetylcholine, glutamate, aspartate and gamma-aminobutyric acid (GABA) measured simultaneously from rat neostriatum using in vivo microdialysis: reciprocal interactions.

Authors:  M Herrera-Marschitz; J J Meana; W T O'Connor; M Goiny; M S Reid; U Ungerstedt
Journal:  Amino Acids       Date:  1992-02       Impact factor: 3.520

10.  Glutamate-evoked release of endogenous brain dopamine: inhibition by an excitatory amino acid antagonist and an enkephalin analogue.

Authors:  K Jhamandas; M Marien
Journal:  Br J Pharmacol       Date:  1987-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.